Cancer Research Meeting Calendar  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 69, 6676, August 15, 2009. Published Online First August 4, 2009;
doi: 10.1158/0008-5472.CAN-09-1208
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-09-1208v1
69/16/6676    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Parra, D.
Right arrow Articles by Soler, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parra, D.
Right arrow Articles by Soler, C.

Molecular Biology, Pathobiology, and Genetics

Increased Susceptibility to Skin Carcinogenesis in TREX2 Knockout Mice

David Parra1, Joan Manils1, Bàrbara Castellana1, Arnau Viña-Vilaseca1, Eva Morán-Salvador1, Nuria Vázquez-Villoldo1, Gemma Tarancón1, Miquel Borràs2, Sara Sancho4, Carmen Benito3, Sagrario Ortega5 and Concepció Soler1

1 Departament de Patologia i Terapèutica Experimental, Facultat de Medicina, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat; 2 Unitat de Toxicologia Experimental, Parc Científic de Barcelona; and 3 Protecció Radiològica, Universitat de Barcelona, Barcelona, Spain; 4 Promed, Fribourg, Switzerland; and 5 Spanish National Cancer Research Center, Madrid, Spain

Requests for reprints: Concepció Soler, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina, Campus de Bellvitge, Universitat de Barcelona, Feixa Llarga s/n, E-08907, L'Hospitalet de Llobregat, Barcelona, Spain. Phone: 34-934039858; Fax: 34-934024249; E-mail: concepciosoler{at}ub.edu.

Key Words: 3'-5' exonuclease • cancer • apoptosis • genomic instability • keratinocyte

TREX2 is a proofreading 3'-5' exonuclease that can be involved in genome maintenance; however, its biological role remains undefined. To better understand the function and physiologic relevance of TREX2, we generated mice deficient in TREX2 by targeted disruption of its unique coding exon. The knockout mice are viable and do not show relevant differences in growth, survival, lymphocyte development, or spontaneous tumor incidence compared with their wild-type counterparts over a period of up to 2 years. Also, we did not observe chromosomal instability or defects in cell proliferation and cell cycle upon loss of TREX2. We have observed that TREX2 expression is not ubiquitous, being expressed preferentially in tissues with stratified squamous epithelia, such as the skin or esophagus, and specifically in keratinocytes. Interestingly, TREX2-null mice are more susceptible to skin carcinogenesis induced by 7,12-dimethylbenz(a)anthracene (DMBA) compared with wild-type mice. This phenotype correlates with a reduction of DMBA-induced apoptosis in both the epidermis and keratinocytes of TREX2-null mice. Altogether, our results suggest a tumor suppressor role for TREX2 in skin carcinogenesis through which it contributes to keratinocyte apoptosis under conditions of genotoxic stress. [Cancer Res 2009;69(16):6676–84]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.